HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HB-0045’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HB-0045 overview

HB-0045 is under development for the treatment of metastatic solid tumors like hepatocellular carcinoma, pancreatic cancer, colorectal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, endometrial cancer, breast cancer, lung cancer, head and neck cancer, prostate cancer, renal cancer, and sarcoma. It is administered through intravenous route and acts by targeting CD73X2.

Huabo Biopharm (Shanghai) overview

Huabo Biopharm Co Ltd (Huabobio), a subsidiary of Shanghai Huaota Biopharmaceutical Co Ltd, is a developer and marketer of therapies for the treatment of patients with tumors. The company develops drugs by using a bi-functional protein technology platform, domain protein technology and antibody engineering technology. Its pipeline products include HOT-101, HB0030, HB0025, HB002.1T, HOT-1030, HB0028, HB0036 and HB0039, among others. Huabobio’s antibody engineering technology and bi-functional protein technology platform support in development of protein and antibody drugs with improved therapeutic efficacy. The company promotes tumor metastasis at the late stage of tumor progression through inducing epithelial-mesenchymal transition, inhibiting tumor immunity; and tumor angiogenesis through induction of angiogenic mediators such as vascular endothelial growth factor. Huabobio is headquartered in Shanghai, China.

For a complete picture of HB-0045’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.